<p>/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)（&#34;Baird Medical&#34;或&#34;公司&#34;）是一家微波消融（MWA）技術的市場領導者，今天宣佈在美國建立一個專門的製造基地。這一發展標誌着 Baird Medical 從專業出口商向綜合全球醫療技術企業轉型的關鍵一步。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847017/BDMD_agreement.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847017/BDMD_agreement.jpg"/></p>
<p>將生產基地設在北美的決定是由於公司在包括印度尼西亞和馬來西亞在內的十多個國家的快速商業成功。為了支持這一國際佈局，Baird Medical 與位於加利福尼亞的 MPS Medical 合作，創建一個集中生產中心。該設施旨在為 Baird Medical 的先進專有技術提供全球市場，確保其不斷擴大的客户羣體的最高質量標準和供應鏈效率。</p>
<p><strong>關於 Baird Medical</strong></p>
<p>Baird Medical 是一家前瞻性的醫療設備公司，專注於微創診斷和治療。公司致力於外科機器人系統和創新微創外科器械的研發。我們的使命是通過精確技術和先進的診斷解決方案提升患者的治療效果。公司將與領先的學術機構建立戰略合作關係。我們的願景超越外科輔助，旨在開發智能系統，主動指導診斷決策和預防醫療策略。作為一家獲得 FDA 510(k) 認證的醫療設備公司，Baird Medical 的解決方案已在美國超過 30 家知名醫院和診所中使用，包括梅奧診所、杜蘭大學醫學中心、哥倫比亞大學醫學中心、加州大學舊金山分校醫學中心、威爾康奈爾醫學中心和喬治華盛頓大學醫院。Baird Medical 在中國的甲狀腺微波消融設備和耗材市場也處於領先地位。同時，公司的微創治療產品正在全球 20 多個國家逐步擴大其商業存在。</p>
<p><strong>關於 MPS Medical</strong></p>
<p>MPS Medical, Inc.是一傢俬人持有的醫療設備公司，在南加州設有辦公室和製造設施。自 30 年前成立以來，MPS 一直致力於提供卓越的醫療設備製造服務和高質量的診斷產品，以改善美國的醫療保健和患者結果。</p>
<p>MPS 最初作為 FDA 批准的醫療設備的製造商和供應商，現在作為美國高質量外國開發醫療技術的許可、製造和分銷中心。MPS 的製造設施面積超過 30,000 平方英尺，包括一個 3,000 平方英尺的 8 級潔淨室和一個 18,000 平方英尺的温控倉庫。該設施同時獲得 FDA 註冊和 ISO 認證。MPS 已獲得 ISO 13485 標準、美國 FDA 21 CFR 第 820 部分質量體系法規和 ISO 14971 醫療設備風險管理標準的認證。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含某些不是歷史事實的聲明，而是根據 1995 年美國私人證券訴訟改革法的安全港條款的前瞻性聲明。前瞻性聲明通常與未來事件或 Baird Medical 未來的財務或運營表現相關。在某些情況下，您可以通過術語如 “可能”、“可以”、“應該”、“期望”、“打算”、“可能”、“將”、“估計”、“預期”、“相信”、“預算”、“預測”、“打算”、“計劃”、“潛在”、“預測” 或這些術語的否定形式或變體或類似術語來識別前瞻性聲明。前瞻性聲明受到風險、不確定性和其他因素的影響，這些因素可能導致實際結果與這些前瞻性聲明所表達或暗示的結果有重大差異。這些前瞻性聲明基於 Baird Medical 及其管理層認為合理的估計和假設，但本質上是不確定的。新的風險和不確定性可能會不時出現，無法預測所有風險和不確定性。您不應對本新聞稿中的前瞻性聲明過度依賴，這些聲明僅在發佈之日有效，並且完全受限於此處的警示聲明。Baird Medical 不承擔更新這些前瞻性聲明的任何義務。</p>
<p>實際結果可能因多種因素而與前瞻性聲明所表達或暗示的結果有重大差異，包括但不限於：（1）Baird Medical 在中國或美國擴展業務可能不成功的風險；（2）一般經濟條件的變化；（3）監管條件和發展；（4）適用法律或法規的變化；（5）對 Baird Medical 或其他人提起的待決和未來訴訟及其他法律程序的性質、成本和結果；（6）在與商業合併相關的註冊聲明和過渡報告中不時描述的其他風險和不確定性，包括在其中標題為 “風險因素” 的部分列出的風險，以及 ExcelFin 向 SEC 的其他文件。</p>
<p>上述因素清單並不排他。有關這些及其他風險因素的更多信息，請參閲 ExcelFin 最近向美國證券交易委員會（SEC）提交的文件，以及 Baird Medical 在與 ExcelFin 的業務合併中提交的上述註冊聲明。所有後續的書面和口頭前瞻性聲明，涉及 Baird Medical、本文所述的業務合併或其他歸因於 Baird Medical 或其代表的任何人的事項，均明確受到上述警示聲明的完全限制。讀者被提醒不要對任何前瞻性聲明過度依賴，這些聲明僅在作出時有效。Baird Medical 明確聲明不承擔任何義務或承諾，公開發布任何前瞻性聲明的更新或修訂，以反映其預期的任何變化或任何基於的事件、條件或情況的變化。</p>
<p><strong>聯繫方式：</strong> Eric Huang，公關聯絡人</p>
<p>Baird Medical Investment Holdings Ltd.</p>
<p>電話：+1 (888) 508-6228</p>
<p>電子郵件：ir@bairdmed.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847018/BDMD_team.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847018/BDMD_team.jpg"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg"/></p>
<p>來源 BDMD</p>

<p>Baird Medical Investment Holdings Ltd.（納斯達克代碼：BDMD）在美國建立了一個製造基地，以支持其全球擴張和未來的研發。與 MPS Medical 合作，新設施將提升 Baird 先進醫療技術的生產和供應鏈效率。Baird Medical 專注於微創診斷和治療，在 20 多個國家和美國的領先醫院中擁有強大的市場存在。該公司旨在開發用於診斷決策和預防醫療策略的智能系統</p>

<p>, /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (&#34;Baird Medical&#34; or the &#34;Company&#34;), a market leader in Microwave Ablation (MWA) technology, today announced the establishment of a dedicated manufacturing base in the United States. This development marks a pivotal step in Baird Medical's transition from a specialized exporter to a comprehensive global medical technology enterprise.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)（&#34;Baird Medical&#34;或&#34;公司&#34;）是一家微波消融（MWA）技術的市場領導者，今天宣佈在美國建立一個專門的製造基地。這一發展標誌着 Baird Medical 從專業出口商向綜合全球醫療技術企業轉型的關鍵一步。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847017/BDMD_agreement.jpg" alt="" original-src="https://mma.prnewswire.com/media/2847017/BDMD_agreement.jpg"/></p>
<p>The decision to anchor production in North America is driven by the Company's rapid commercial success across over a dozen countries, including recent significant market penetrations in Indonesia and Malaysia. To support this international footprint, Baird Medical has partnered with California-based MPS Medical to create a centralized production hub. This facility is designed to supply Baird Medical's advanced proprietary technologies to global markets, ensuring the highest standards of quality and supply chain efficiency for its expanding client base.</p>
<div class="lb-trans"><p>將生產基地設在北美的決定是由於公司在包括印度尼西亞和馬來西亞在內的十多個國家的快速商業成功。為了支持這一國際佈局，Baird Medical 與位於加利福尼亞的 MPS Medical 合作，創建一個集中生產中心。該設施旨在為 Baird Medical 的先進專有技術提供全球市場，確保其不斷擴大的客户羣體的最高質量標準和供應鏈效率。</p>
</div><p><strong>About Baird Medical</strong></p>
<div class="lb-trans"><p><strong>關於 Baird Medical</strong></p>
</div><p>Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.</p>
<div class="lb-trans"><p>Baird Medical 是一家前瞻性的醫療設備公司，專注於微創診斷和治療。公司致力於外科機器人系統和創新微創外科器械的研發。我們的使命是通過精確技術和先進的診斷解決方案提升患者的治療效果。公司將與領先的學術機構建立戰略合作關係。我們的願景超越外科輔助，旨在開發智能系統，主動指導診斷決策和預防醫療策略。作為一家獲得 FDA 510(k) 認證的醫療設備公司，Baird Medical 的解決方案已在美國超過 30 家知名醫院和診所中使用，包括梅奧診所、杜蘭大學醫學中心、哥倫比亞大學醫學中心、加州大學舊金山分校醫學中心、威爾康奈爾醫學中心和喬治華盛頓大學醫院。Baird Medical 在中國的甲狀腺微波消融設備和耗材市場也處於領先地位。同時，公司的微創治療產品正在全球 20 多個國家逐步擴大其商業存在。</p>
</div><p><strong>About MPS Medical</strong></p>
<div class="lb-trans"><p><strong>關於 MPS Medical</strong></p>
</div><p>MPS Medical, Inc. is a privately held medical device company with offices and manufacturing facilities Southern California. Since its founding 30 years ago, MPS has been committed to providing exceptional medical device manufacturing services and high-quality diagnostic products to help improve healthcare and patient outcomes throughout the United States.</p>
<div class="lb-trans"><p>MPS Medical, Inc.是一傢俬人持有的醫療設備公司，在南加州設有辦公室和製造設施。自 30 年前成立以來，MPS 一直致力於提供卓越的醫療設備製造服務和高質量的診斷產品，以改善美國的醫療保健和患者結果。</p>
</div><p>MPS was founded as a manufacturer and supplier of FDA-approved medical devices and now serves as a U.S. hub for the licensing, manufacturing, and distribution of high-quality, foreign-developed medical technologies. MPS manufacturing facility is over 30,000 sq ft, including a 3,000 sq ft class 8 cleanroom and an 18,000 sq ft temperature-controlled warehouse. The facility is both FDA registered and ISO certified. MPS's is certified to ISO 13485 standards, US FDA 21 CFR Part 820 Quality System regulations and ISO 14971 Medical Device, Risk Management standards.</p>
<div class="lb-trans"><p>MPS 最初作為 FDA 批准的醫療設備的製造商和供應商，現在作為美國高質量外國開發醫療技術的許可、製造和分銷中心。MPS 的製造設施面積超過 30,000 平方英尺，包括一個 3,000 平方英尺的 8 級潔淨室和一個 18,000 平方英尺的温控倉庫。該設施同時獲得 FDA 註冊和 ISO 認證。MPS 已獲得 ISO 13485 標準、美國 FDA 21 CFR 第 820 部分質量體系法規和 ISO 14971 醫療設備風險管理標準的認證。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as &#34;may&#34;, &#34;could&#34;, &#34;should&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;might&#34;, &#34;will&#34;, &#34;estimate&#34;, &#34;anticipate&#34;, &#34;believe&#34;, &#34;budget&#34;, &#34;forecast&#34;, &#34;intend&#34;, &#34;plan&#34;, &#34;potential&#34;, &#34;predict&#34;, or &#34;continue&#34;, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.</p>
<div class="lb-trans"><p>本新聞稿包含某些不是歷史事實的聲明，而是根據 1995 年美國私人證券訴訟改革法的安全港條款的前瞻性聲明。前瞻性聲明通常與未來事件或 Baird Medical 未來的財務或運營表現相關。在某些情況下，您可以通過術語如 “可能”、“可以”、“應該”、“期望”、“打算”、“可能”、“將”、“估計”、“預期”、“相信”、“預算”、“預測”、“打算”、“計劃”、“潛在”、“預測” 或這些術語的否定形式或變體或類似術語來識別前瞻性聲明。前瞻性聲明受到風險、不確定性和其他因素的影響，這些因素可能導致實際結果與這些前瞻性聲明所表達或暗示的結果有重大差異。這些前瞻性聲明基於 Baird Medical 及其管理層認為合理的估計和假設，但本質上是不確定的。新的風險和不確定性可能會不時出現，無法預測所有風險和不確定性。您不應對本新聞稿中的前瞻性聲明過度依賴，這些聲明僅在發佈之日有效，並且完全受限於此處的警示聲明。Baird Medical 不承擔更新這些前瞻性聲明的任何義務。</p>
</div><p>Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled &#34;Risk Factors&#34; therein, and in ExcelFin's other filings with the SEC.</p>
<div class="lb-trans"><p>實際結果可能因多種因素而與前瞻性聲明所表達或暗示的結果有重大差異，包括但不限於：（1）Baird Medical 在中國或美國擴展業務可能不成功的風險；（2）一般經濟條件的變化；（3）監管條件和發展；（4）適用法律或法規的變化；（5）對 Baird Medical 或其他人提起的待決和未來訴訟及其他法律程序的性質、成本和結果；（6）在與商業合併相關的註冊聲明和過渡報告中不時描述的其他風險和不確定性，包括在其中標題為 “風險因素” 的部分列出的風險，以及 ExcelFin 向 SEC 的其他文件。</p>
</div><p>The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</p>
<div class="lb-trans"><p>上述因素清單並不排他。有關這些及其他風險因素的更多信息，請參閲 ExcelFin 最近向美國證券交易委員會（SEC）提交的文件，以及 Baird Medical 在與 ExcelFin 的業務合併中提交的上述註冊聲明。所有後續的書面和口頭前瞻性聲明，涉及 Baird Medical、本文所述的業務合併或其他歸因於 Baird Medical 或其代表的任何人的事項，均明確受到上述警示聲明的完全限制。讀者被提醒不要對任何前瞻性聲明過度依賴，這些聲明僅在作出時有效。Baird Medical 明確聲明不承擔任何義務或承諾，公開發布任何前瞻性聲明的更新或修訂，以反映其預期的任何變化或任何基於的事件、條件或情況的變化。</p>
</div><p><strong>Contact:</strong> Eric Huang, PR Liaison</p>
<div class="lb-trans"><p><strong>聯繫方式：</strong> Eric Huang，公關聯絡人</p>
</div><p>Baird Medical Investment Holdings Ltd.</p>
<div class="lb-trans"><p>Baird Medical Investment Holdings Ltd.</p>
</div><p>Phone: +1 (888) 508-6228</p>
<div class="lb-trans"><p>電話：+1 (888) 508-6228</p>
</div><p>Email: ir@bairdmed.com</p>
<div class="lb-trans"><p>電子郵件：ir@bairdmed.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2847018/BDMD_team.jpg" alt="" original-src="https://mma.prnewswire.com/media/2847018/BDMD_team.jpg"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg"/></p>
<p>SOURCE BDMD</p>
<div class="lb-trans"><p>來源 BDMD</p>
</div>

貝爾德醫療在美國建立製造基地，以加速其全球擴張和未來的研發 | BDMD 股票新聞